Expanding the therapeutic repertoire of epidermal growth factor receptor blockade: radiosensitization [Commentary]

Gee, Julia Margaret Wendy ORCID: https://orcid.org/0000-0001-6483-2015 and Nicholson, Robert Ian 2003. Expanding the therapeutic repertoire of epidermal growth factor receptor blockade: radiosensitization [Commentary]. Breast Cancer Research 5 (3) , pp. 126-129. 10.1186/bcr584

Preview

PDF - Published Version Available under License Creative Commons Attribution. Download (49kB) | Preview

Abstract

Expression of epidermal growth factor receptor (EGFR) has been associated with radioresistance in cancer. Moreover, tumour cell recovery after irradiation paradoxically occurs, in part, as a result of activation of EGFR signalling by such treatment. A recent article by Huang, Li, Armstrong and Harari provides strong rationale for considering the anti-EGFR agent ZD1839 ('Iressa') as a radiosensitizing strategy. With the use of several in vitro and xenograft models of human squamous cell head and neck carcinoma, ZD1939 was shown to markedly improve radiotherapeutic response, with superior tumour inhibition and delayed tumour regrowth. Mechanisms underlying this effect included anti-proliferative and pro-apoptotic activity, with significant perturbation of tumour angiogenesis.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Pharmacy
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) R Medicine > RM Therapeutics. Pharmacology
Uncontrolled Keywords:	angiogenesis; EGFR; radiotherapy; resistance; ZD1839
Publisher:	BioMed Central
ISSN:	1465-5411
Date of First Compliant Deposit:	30 March 2016
Last Modified:	16 May 2023 04:33
URI:	https://orca.cardiff.ac.uk/id/eprint/17102

Citation Data

Cited 21 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item